Weekly Investment Analysts’ Ratings Changes for Seaport Therapeutics (SPTX)

Seaport Therapeutics (NASDAQ: SPTX) recently received a number of ratings updates from brokerages and research firms:

• 10/8/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 10/8/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 9/25/2026 – Seaport Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/25/2026 – Seaport Therapeutics was given a new $46.00 price target by Seaport Research Partners.
• 9/25/2026 – Seaport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 9/25/2026 – Seaport Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 9/10/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/26/2026 – Seaport Therapeutics is now covered by JonesTrading. They set a “buy” rating and a $32.00 price target on the stock.
• 8/25/2026 – Seaport Therapeutics was given a new $32.00 price target by Seaport Research Partners.
• 8/20/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for neuropsychiatric and neurological disorders. The company’s research emphasizes therapies that modulate the brain’s GABAergic system, which plays an important role in mood, anxiety, and other central nervous system functions.

Seaport’s drug-development programs are based on its Glyph platform, a technology designed to improve the delivery of small-molecule medicines to the brain and enable oral versions of therapies that may otherwise require intravenous or other forms of administration.